Arcadia Biosciences Inc. Common Stock (RKDA)

FairStock Score: 56/100 — STEADY

Key Financials

Strengths

• Generates $721,750 in annual free cash flow (32.8% yield on market cap)
• Healthy net profit margin of 17.6% showing consistent profitability

Concerns

• Revenue declining at 25.9% year-over-year signals potential demand weakness or market share loss
• Weak Piotroski F-Score of 1/9 suggests deteriorating financial quality across multiple dimensions
• Altman Z-Score of -59.4 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Arcadia Biosciences Inc. Common Stock is a micro-cap consumer defensive company valued at $2 million. The business generates $5 million in annual revenue with a 17.6% net margin and $721,750 in free cash flow. From a quality standpoint, Arcadia shows weak Piotroski F-Score of 1/9 signaling deteriorating fundamentals and distressed Altman Z-Score of -59.4 warrants caution. Growth dynamics show revenue growing at -25.9% and profit growth of 67.1%. Our composite FairStock Score of 56/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $721,750 in annual free cash flow (32.8% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the consumer defensive space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer